New Amar Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.20 Cr
as on 18-10-2024
- Paid Up Capital ₹ 5.01 Cr
as on 18-10-2024
- Company Age 2 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 34.53 Cr
as on 18-10-2024
- Revenue 2186.30%
(FY 2024)
- Profit -318.38%
(FY 2024)
- Ebitda 2276.63%
(FY 2024)
- Net Worth 1.28%
(FY 2024)
- Total Assets 31.93%
(FY 2024)
About New Amar Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.20 Cr and a paid-up capital of Rs 5.01 Cr.
The company currently has active open charges totaling ₹34.53 Cr.
Gilan Ferzandi, Gaurav Chaturvedi, Nilesh Sonigara, and One other member serve as directors at the Company.
- CIN/LLPIN
U51909MH2022PTC377993
- Company No.
377993
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Mar 2022
- Date of AGM
26 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at New Amar Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilesh Sonigara  | Managing Director | 27-Jul-2022 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Gaurav Chaturvedi | Director | 02-Feb-2024 | Current |
| Gilan Ferzandi | Director | 07-Mar-2022 | Current |
| Yaaresh Ferzandi | Director | 07-Mar-2022 | Current |
Financial Performance of New Amar Pharmaceuticals.
New Amar Pharmaceuticals Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 2186.3% increase. The company also saw a substantial fall in profitability, with a 318.38% decrease in profit. The company's net worth moved up by a moderate rise of 1.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of New Amar Pharmaceuticals?
In 2023, New Amar Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pharmacare Logistics Private LimitedActive 15 years 8 monthsGilan Ferzandi and Yaaresh Ferzandi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 16 Mar 2024 | ₹33.00 Cr | Open |
Hdfc Bank Limited Creation Date: 01 Dec 2023 | ₹1.53 Cr | Open |
How Many Employees Work at New Amar Pharmaceuticals?
New Amar Pharmaceuticals has a workforce of 279 employees as of Oct 18, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of New Amar Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped New Amar Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
